In cultured MDMs obtained from SSc-ILD patients, nintedanib at the concentrations of 0.1 and 1μM significantly downregulated the gene expression of CD204, CD206, and CD163 compared to untreated cells after 24 h of treatment (p < 0.05 for all phenotype markers) (Fig. 3). This evidence concerns the gene MRC1 and systemic sclerosis.